Antipsychotic Drugs: Technologies and Global Markets
Report Scope:
This report provides a detailed description of the market for antipsychotic drugs. The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players. The report segments the market for antipsychotic drugs based on mechanism of action, disease indication and geography. Based on mechanism of action, the market is segmented into D2 antagonists, D2/5HT2A antagonists and D2 partial agonists. The market size includes both branded and generic drugs. Based on disease indication, the market is segmented into schizophrenia, bipolar disorder, major depressive disorder (MDD), and other diseases including anxiety, autism and dementia. By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. The North America region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., France, Italy, Spain and the rest of Europe. Asia-Pacific includes China, India, Japan and the rest of Asia-Pacific. For market estimates, data has been provided for 2017 as the base year, with forecasts for 2018 through 2023.
Report Includes:
- 22 data tables and 36 additional tables
- An overview of the global market for antipsychotic drugs
- Analyses of global market trends, with data from 2017, estimates for 2018 and projections of CAGRs through 2023
- Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, Spain, China, India and Japan
- Definition, history and types of antipsychotic drugs
- An understanding on receptor target of antipsychotic drugs, including dopamine, serotonin, glutamate, tachykinin and glucocorticoid
- Coverage of various psychotic diseases and their indication including schizophrenia, bipolar disorder, major depressive disorder (MDD), anxiety, autism and dementia
- Comprehensive company profiles of key players in the market, including Alexza Pharmaceuticals, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Co., Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA), Inc.
- Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Highlights
- Chapter 3 Market and Technology Background
- Overview: Antipsychotic Drugs
- History of Antipsychotic Drugs
- Types of Antipsychotic Drugs
- Typical Antipsychotic Drugs
- Atypical Antipsychotic Drugs
- Receptor Target of Antipsychotic Drugs
- Dopamine
- Serotonin
- Glutamate
- Tachykinin
- Glucocorticoid
- Technology Overview
- Formulations
- Combination Therapies
- Chapter 4 Market Dynamics
- Market Drivers
- Rising Incidence of Mental Disorders (Schizophrenia and Bipolar Disorder)
- Government and NGO Initiatives in Creating Awareness Regarding Mental Illness
- Growing Geriatric Population with Mental Disorders
- Increasing Prevalence of Depression and Anxiety
- Market Restraints
- Patent Expirations of Branded Drugs and Emergence of Generics
- Adverse Side Effects Associated with Antipsychotic Drugs
- Market Opportunities
- Unmet Needs in Low-and Middle-Income Countries
- Widening Disease Indication Areas for Antipsychotic Drugs
- Loss of Patent Exclusivity: Lucrative Opportunity for Generic Manufacturers
- Chapter 5 Market Breakdown by Mechanism of Action
- Global Antipsychotic Drug Market
- D2 Antagonists
- Market Size and Forecast
- Market Analysis
- D2/5HT2A Antagonists
- Market Size and Forecast
- Market Analysis
- D2 Partial Agonists
- Market Size and Forecast
- Market Analysis
- Chapter 6 Market Breakdown by Disease Indication
- Global Antipsychotic Drugs Market, by Disease Indication
- Schizophrenia
- Overview
- Market Size and Forecast
- Market Analysis
- Bipolar Disorder
- Overview
- Market Size and Forecast
- Market Analysis
- Major Depressive Disorder
- Overview
- Market Size and Forecast
- Market Analysis
- Other Disease Indications
- Overview
- Market Size and Forecast
- Market Analysis
- Chapter 7 Market Breakdown by Region
- Global Market for Antipsychotic Drugs, by Region
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- South America
- Prevalence of Mental Illness in South America
- Middle East and Africa
- Prevalence of Mental Illness in the Middle East and Africa
- Chapter 8 Regulatory Scenario
- Regulations in the U.S.
- New Drug Approval
- Controlled Substances Act
- The FDA Modernization Act of 1997
- Fast Track Status
- Special Protocol Assessments
- New Surveillance and Safety Requirements
- Medicare
- Regulations in Europe
- Pricing and Reimbursement
- Regulations in Japan
- Chapter 9 Patent Analysis
- Patent Lengths and Market Exclusivity
- Chapter 10 Pipeline Analysis
- Overview of the Drug Development Process
- Pipeline Analysis of Antipsychotic Drugs
- Drugs in Phase I Clinical Trials
- Drugs in Phase II Clinical Trials
- Drugs in Phase II Clinical Trials
- Late Stage Clinical Trials for Novel Drug Candidates
- Chapter 11 Competitive Landscape
- Global Company Share Analysis
- Impact of Generic Antipsychotic Drugs on the Market
- Chapter 12 Company Profiles
- ACADIA PHARMACEUTICALS, INC.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- ALEMBIC PHARMACEUTICALS, LTD.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- ALEXZA PHARMACEUTICALS
- Company Overview
- Product Portfolio
- Development and Strategies
- ALKERMES PLC
- Company Overview
- Financials
- Regional Revenue
- Product Portfolio
- Development and Strategies
- ALLERGAN PLC
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- APOTEX, INC.
- Company Overview
- Product Portfolio
- Development and Strategies
- ASTRAZENECA PLC
- Company Overview
- Financials
- AstraZeneca PLC Business Segment Revenue
- AstraZeneca PLC Revenue by Region Segment
- Product Portfolio
- Development and Strategies
- AUROBINDO PHARMA
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- DR. REDDY'S LABORATORIES LTD.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- ELI LILLY AND CO.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- GEDEON RICHTER PLC
- Company Overview
- Financials
- Gedeon Richter PLC Business Segment Revenue
- Gedeon Richter PLC Revenue by Region
- Product Portfolio
- Development and Strategies
- JOHNSON & JOHNSON
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- LANNETT CO., INC.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- H. LUNDBECK A/S
- Company Overview
- Financials
- H. Lundbeck A/S Region Segment Revenue
- Product Portfolio
- Development and Strategies
- LUPIN, LTD.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- MAYNE PHARMA, INC.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- MYLAN NV
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- OTSUKA HOLDINGS CO., LTD.
- Company Overview
- Financials
- Otsuka Holdings Co. Ltd. Revenue by Business Segment
- Otsuka Holdings Co., Ltd. Revenue by Region
- Product Portfolio
- Development and Strategies
- SUMITOMO DAINIPPON PHARMA CO., LTD.
- Company Overview
- Financials
- Sumitomo Dainippon Pharma Co. Ltd. Revenue by Region
- Product Portfolio
- Development and Strategies
- SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- TORRENT PHARMACEUTICALS, LTD.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- VANDA PHARMACEUTICALS, INC
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- WOCKHARDT
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- ZYDUS PHARMACEUTICALS (USA), INC.
- Company Overview
- Financials
- Product Portfolio
- Development and Strategies
- Chapter 13 List of Abbreviations
- List of Tables
- Summary Table : Global Market for Antipsychotic Drugs, by Mechanism of Action, Through 2023
- Table 1 : Currently Approved Atypical Antipsychotics in the Market
- Table 2 : Administration Profile of Long-acting Atypical Antipsychotic Drugs
- Table 3 : Number of Bipolar Disorder Patients, by Country, 2018
- Table 4 : Patent Expiration Dates for Antipsychotic Drugs
- Table 5 : Number of Warnings About Antipsychotic Drugs
- Table 6 : Abilify Revenue, 2014-2017
- Table 7 : Indicative List of Available Generic Versions of Abilify
- Table 8 : Global Market for Antipsychotic Drugs, by Mechanism of Action, Through 2023
- Table 9 : D2 Antagonist Drugs: Market Presence
- Table 10 : Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs
- Table 11 : Global Market for Antipsychotic Drugs, by Disease Indication, Through 2023
- Table 12 : Global Market for Antipsychotic Drugs, by Region, Through 2023
- Table 13 : North American Market for Antipsychotic Drugs, by Country, Through 2023
- Table 14 : Prevalence of Serious Mental Illness Among Adults, by State, U.S., 2017
- Table 15 : Prevalence of Mental Illness, by Disease Indication, U.S., 2017
- Table 16 : Prevalence of Mental Illness, by Disease Indication, Canada
- Table 17 : European Market for Antipsychotic Drugs, by Country, Through 2023
- Table 18 : Prevalence of Mental Illness, by Disease Indication, Germany, 2016
- Table 19 : Prevalence of Mental Illness, by Disease Indication, U.K., 2017
- Table 20 : Prevalence of Mental Illness, by Disease Indication, France, 2014
- Table 21 : Prevalence of Mental Illness, by Disease Indication, Italy, 2017
- Table 22 : Prevalence of Mental Illness, by Disease Indication, Spain, 2016
- Table 23 : Asia-Pacific Market for Antipsychotic Drugs, by Country, Through 2023
- Table 24 : Prevalence of Mental Illness, by Disease Indication, Japan, 2017
- Table 25 : Prevalence of Mental Illness, by Disease Indication, China, 2017
- Table 26 : Prevalence of Mental Illness, by Disease Indication, India, 2016
- Table 27 : Patent Expiration of Antipsychotic Drugs
- Table 28 : Exclusivity Expiration of Antipsychotic Drugs
- Table 29 : Phase I Pipeline of Antipsychotic Drugs
- Table 30 : Phase II Pipeline of Antipsychotic Drugs
- Table 31 : Phase III Pipeline of Antipsychotic Drugs
- Table 32 : Acadia Pharmaceuticals: Antipsychotic Drugs Product Portfolio
- Table 33 : Alembic Pharmaceuticals, Ltd.: Antipsychotic Drugs Product Portfolio
- Table 34 : Alexza Pharmaceuticals: Antipsychotic Drugs Product Portfolio
- Table 35 : Alkermes PLC: Antipsychotic Drugs Product Portfolio
- Table 36 : Allergan PLC: Antipsychotic Drugs Product Portfolio
- Table 37 : Apotex, Inc.: Antipsychotic Drugs Product Portfolio
- Table 38 : AstraZeneca PLC: Antipsychotic Drugs Product Portfolio
- Table 39 : Aurobindo Pharma: Antipsychotic Drugs Product Portfolio
- Table 40 : Dr. Reddy’s Laboratories, Ltd.: Antipsychotic Drugs Product Portfolio
- Table 41 : Eli Lilly and Co.: Products
- Table 42 : Gedeon Richter PLC: Antipsychotic Drugs Product Portfolio
- Table 43 : Johnson & Johnson: Antipsychotic Drugs Product Portfolio
- Table 44 : Lannett Co.: Antipsychotic Drugs Product Portfolio
- Table 45 : H. Lundbeck A/S: Antipsychotic Drugs Product Portfolio
- Table 46 : Lupin, Ltd.: Antipsychotic Drugs Product Portfolio
- Table 47 : Mayne Pharma, Inc.: Antipsychotic Drugs Product Portfolio
- Table 48 : Mylan NV: Antipsychotic Drugs Product Portfolio
- Table 49 : Otsuka Holdings Co., Ltd.: Antipsychotic Drugs Product Portfolio
- Table 50 : Sumitomo Dainippon Pharma Co., Ltd.: Antipsychotic Drugs Product Portfolio
- Table 51 : Sun Pharmaceuticals Industries, Ltd.: Antipsychotic Drugs Product Portfolio
- Table 52 : Teva Pharmaceutical Industries, Ltd.: Antipsychotic Drugs Product Portfolio
- Table 53 : Torrent Pharmaceuticals, Ltd.: Antipsychotic Drugs Product Portfolio
- Table 54 : Vanda Pharmaceuticals, Inc.: Antipsychotic Drugs Product Portfolio
- Table 55 : Wockhardt: Antipsychotic Drugs Product Portfolio
- Table 56 : Zydus Pharmaceuticals (USA), Inc.: Antipsychotic Drugs Product Portfolio
- Table 57 : Abbreviations Used in Antipsychotic Drugs: Technologies and Global Markets
- List of Figures
- Summary Figure : Global Market Share for Antipsychotic Drugs, by Mechanism of Action, 2017
- Figure 1 : Number of Depressive Disorder Patients, by Region, 2015
- Figure 2 : Number of Patients with Anxiety Disorders, by Region, 2015
- Figure 3 : Global Market Share for Antipsychotic Drugs, by Mechanism of Action, 2017
- Figure 4 : Global Market for Antipsychotic Drugs in D2 Antagonist, 2017-2023
- Figure 5 : Global Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2017-2023
- Figure 6 : Eli Lilly and Company: Sales Revenue for Zyprexa Franchise, 2014-2017
- Figure 7 : Johnson & Johnson: Sales Revenue for Invega, 2012-2015
- Figure 8 : Johnson & Johnson Sales Revenue for Invega Sustenna Franchise, 2014-2017
- Figure 9 : Johnson & Johnson: Sales Revenue for Risperdal Consta, 2014-2017
- Figure 10 : AstraZeneca: Sales Revenue for Seroquel IR, 2014-2017
- Figure 11 : AstraZeneca: Sales Revenue for Seroquel XR, 2014-2017
- Figure 12 : Sumitomo Dainippon Pharma Co. Ltd.: Sales Revenue for Latuda, 2015-2017
- Figure 13 : Sumitomo Dainippon Pharma Co. Ltd.: Sales Revenue for Lonasen, 2015-2017
- Figure 14 : Vanda Pharmaceuticals: Sales Revenue for Fanapt Franchise, 2015-2017
- Figure 15 : Allergan: Sales Revenue for Saphris, 2015-2017
- Figure 16 : Global Market for Antipsychotic Drugs in D2 Partial Agonist, 2017-2023
- Figure 17 : Otsuka Holdings Co. Ltd.: Sales Revenue for Abilify, 2014-2017
- Figure 18 : Otsuka Holdings Co. Ltd.: Sales Revenue for Abilify Maintena, 2015-2017
- Figure 19 : Otsuka Holdings Co. Ltd.: Sales Revenue for Rexulti, 2015-2017
- Figure 20 : Alkermes: Sales Revenue for Aristada, 2015-2017
- Figure 21 : Allergan: Sales Revenue for Vraylar, 2016 and 2017
- Figure 22 : Global Market Share for Antipsychotic Drugs, by Disease Indication, 2017
- Figure 23 : Global Market for Antipsychotic Drugs in Schizophrenia, 2017-2023
- Figure 24 : Global Market for Antipsychotic Drugs in Bipolar Disorder, 2017-2023
- Figure 25 : Global Market for Antipsychotic Drugs in Major Depressive Disorder (MDD), 2017-2023
- Figure 26 : Global Market for Antipsychotic Drugs in Other Disease Indications, 2017-2023
- Figure 27 : Global Market Share for Antipsychotic Drugs, by Region, 2017
- Figure 28 : North American Market Share for Antipsychotic Drugs, by Country, 2017
- Figure 29 : U.S. Market for Antipsychotic Drugs, 2017-2023
- Figure 30 : Canadian Market for Antipsychotic Drugs, 2017-2023
- Figure 31 : Mexican Market for Antipsychotic Drugs, 2017-2023
- Figure 32 : European Market Share for Antipsychotic Drugs, by Country, 2017
- Figure 33 : German Market for Antipsychotic Drugs, 2017-2023
- Figure 34 : U.K. Market for Antipsychotic Drugs, 2017-2023
- Figure 35 : French Market for Antipsychotic Drugs, 2017-2023
- Figure 36 : Italian Market for Antipsychotic Drugs, 2017-2023
- Figure 37 : Spanish Market for Antipsychotic Drugs, 2017-2023
- Figure 38 : Rest of Europe Market for Antipsychotic Drugs, 2017-2023
- Figure 39 : Asia-Pacific Market Share for Antipsychotic Drugs, by Country, 2017
- Figure 40 : Japanese Market for Antipsychotic Drugs, 2017-2023
- Figure 41 : Chinese Market for Antipsychotic Drugs, 2017-2023
- Figure 42 : Indian Market for Antipsychotic Drugs, 2017-2023
- Figure 43 : Rest of Asia-Pacific Market for Antipsychotic Drugs, 2017-2023
- Figure 44 : South American Market for Antipsychotic Drugs, 2017-2023
- Figure 45 : Middle East and African Market for Antipsychotic Drugs, 2017-2023
- Figure 46 : Global Market Share for Antipsychotic Drugs, by Manufacturer, 2017
- Figure 47 : Acadia Pharmaceuticals: Financial Performance, 2016 and 2017
- Figure 48 : Alembic Pharmaceuticals, Ltd.: Financial Performance, 2015-2017
- Figure 49 : Alkermes PLC: Annual Revenue, 2014-2017
- Figure 50 : Alkermes PLC: Revenue Share, by Region, 2017
- Figure 51 : Allergan PLC: Annual Revenue, 2013-2017
- Figure 52 : Allergan PLC: Revenue Share, by Business Unit, 2017
- Figure 53 : AstraZeneca PLC: Financial Performance, 2013-2017
- Figure 54 : AstraZeneca PLC: Revenue Share, by Business Unit, 2017
- Figure 55 : AstraZeneca PLC: Revenue Share, by Region, 2017
- Figure 56 : Aurobindo Pharma: Financial Performance, 2015-2017
- Figure 57 : Dr. Reddy’s Laboratories, Ltd.: Financial Performance, 2015-2017
- Figure 58 : Eli Lilly and Co.: Revenue, 2013-2017
- Figure 59 : Eli Lilly and Co.: Revenue Share, by Region, 2017
- Figure 60 : Eli Lilly and Co.: Revenue Share, by Business Unit, 2017
- Figure 61 : Gedeon Richter PLC: Financial Performance, 2014-2017
- Figure 62 : Gedeon Richter PLC: Revenue Share, by Business Unit, 2017
- Figure 63 : Gedeon Richter PLC: Revenue Share, by Region, 2017
- Figure 64 : Johnson & Johnson: Revenue, 2013-2017
- Figure 65 : Johnson & Johnson: Revenue Share, by Region, 2017
- Figure 66 : Johnson & Johnson: Revenue Share, by Business Unit, 2017
- Figure 67 : Lannett Co.: Financial Performance, 2015-2017
- Figure 68 : H. Lundbeck A/S: Financial Performance, 2013-2017
- Figure 69 : H. Lundbeck A/S: Revenue Share, by Region, 2017
- Figure 70 : Lupin, Ltd.: Financial Performance, 2015-2017
- Figure 71 : Lupin, Ltd.: Revenue Shares, by Business Segment, 2017
- Figure 72 : Mayne Pharma, Inc.: Financial Performance, 2015-2017
- Figure 73 : Mylan NV: Financial Performance, 2014-2017
- Figure 74 : Mylan NV: Revenue Share, by Region, 2017
- Figure 75 : Otsuka Holdings Co., Ltd.: Financial Performance, 2013-2017
- Figure 76 : Otsuka Holdings Co., Ltd.: Revenue Share, by Business Unit, 2017
- Figure 77 : Otsuka Holdings Co., Ltd.: Revenue Share, by Region, 2017
- Figure 78 : Sumitomo Dainippon Pharma Co., Ltd.: Financial Performance, 2013-2017
- Figure 79 : Sumitomo Dainippon Pharma Co. Ltd.: Revenue Shares, by Region, 2017
- Figure 80 : Sun Pharmaceuticals Industries, Ltd.: Financial Performance, 2015-2017
- Figure 81 : Teva Pharmaceutical Industries, Ltd.: Financial Performance, 2015-2017
- Figure 82 : Teva Pharmaceutical Industries, Ltd.: Revenue Share, by Region, 2017
- Figure 83 : Teva Pharmaceutical Industries, Ltd.: Revenue Share, by Business Segment, 2016
- Figure 84 : Torrent Pharmaceuticals, Ltd.: Financial Performance, 2015-2017
- Figure 85 : Vanda Pharmaceuticals, Inc.: Annual Revenue, 2013-2017
- Figure 86 : Wockhardt: Financial Performance, 2015-2017
- Figure 87 : Wockhardt: Revenue Share, by Region, 2017
- Figure 88 : Zydus Pharmaceuticals (USA), Inc.: Financial Performance, 2015-2017
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook